Skip to main content
OpenTrials
Completed

NCT Number: NCT03789669

A Prospective, Multi-Center Evaluation of Corneal Flap Creation Using Cheetah Femtosecond Laser System and Cheetah Patient Interface

The study is a prospective, open-label, comparative study design that was chosen for the purpose of optimizing the Cheetah settings, and evaluating the Cheetah system quality of LASIK flap.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Narayana Nethralaya Eye Hospital, RajajiNagar, Bangalore, India

Loading trial locations.

About this study

This study is a 3-month, prospective, multicenter, open-label, comparative, randomized (1:1 ratio for right and left eyes) study.

The study will be conducted at up to 5 sites and up to 300 treated subjects to achieve minimum 40 eyes with optimized settings and additional eye data for further device experience.

Both eyes of each subject will be treated. The investigator will use the Cheetah femtosecond laser, with the following possible procedures performed:

A comparison of commercial iFS femtosecond laser and PI in one eye and the Cheetah femtosecond laser (with the two piece PI) on the other eye. The eye treated with the Cheetah femtosecond laser will be the study eye and the eye treated with the commercial iFS femtosecond laser will be the control eye.

All procedures will be performed to create a LASIK flap on subjects' corneas. Flap parameters (such as flap depth, flap diameter, and hinge angle) should be the same for both eyes. The study eye will be randomized (ratio of 1:1 for right eye and left eye).

Subjects will undergo refractive correction via corneal ablation on both eyes using a commercial excimer laser for vision correction (same excimer laser system shall be used on both eyes).

Over the course of the study, minor prototype device settings/improvements (with no safety implications and without compromising the clinical validity of the study) may be performed to optimize the quality of flap.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

To be considered for enrollment of the study, subject must:

  • Sign an informed consent and HIPAA authorization
  • Be at least 18 years of age at the time of study exam
  • Have refractive error and be eligible for commercial LASIK treatment
  • Be available for all scheduled follow-up visits (see below)

Exclusion criteria

Subject will not be eligible to take part of the study if subject, use or have:

  • Known to be pregnant, breastfeeding or intend to become pregnant during the study.
  • Recent ocular (eye) trauma or eye surgery
  • A history of or active ophthalmic (eye) disease or abnormality
  • Ocular hypertension (high eye pressure) with IOP (eye pressure) greater than 21 mmHg, glaucoma suspect, or are taking medications for these conditions
  • A history or current diagnosis of any of the following medical conditions that could affect wound healing: collagen vascular disease, autoimmune disease, immunodeficiency disease, ocular herpes; endocrine disorders including, but not limited to unstable thyroid disorders and diabetes, lupus, and rheumatoid arthritis.
  • Cardiac pacemaker, implanted defibrillator or other implanted electronic device
  • Taking systemic or inhaled medications that may affect wound healing
  • Known sensitivity or inappropriate responsiveness to any of the medications used in the study
  • Desire for monovision correction
  • Participating in any other clinical study

Treatment and study plan

IntraLase iFS femtosecond laser and patient interface

Device

Commercial ophthalmic laser surgical system

Cheetah femtosecond laser and cheetah patient interface

Device

Ophthalmic laser surgical system

Primary outcomes

  1. Stromal Bed Surface Quality

    Time frame: At the Operative visit, one time visit

    Surface quality will be graded on a scale of 1-5 relative to Intralase iFS flap. Number of Participants with Stromal Bed Surface Quality scale of 3 or higher.

Other outcomes

  1. Flap Thickness

    Time frame: 3 months

    The central flap thickness is measured per each eye, compared from ELITA vs. iFS performances.

Sponsors and collaborators

Lead sponsor

Johnson & Johnson Surgical Vision, Inc.

Industry

Registry information

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Dec 28, 2018
Registry last updated
May 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.